Last Updated on May 26, 2024 by The Health Master

NPPA

Download NPPA notification No. S.O. 1991 (E) dt 15-05-2024, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 4 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 1991(E) dt 15-04-2024 based on the decision of 123rd Authority meeting dated 10-05-2024.

The notification states as follows:

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

A table is given below the article

Note:

(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-mentioned table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above, i.e., those who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to the fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes or rules,
including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of the manufacturer and marketing company specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and marketing company
Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.

Table

Sl. No.	Medicines	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Ceftazidime and Avibactam powder for concentrate for solution for infusion	Each vial contains: Ceftazidime Pentahydrate IP eq. to Ceftazidime                               2.0gm Avibactam Sodium eq. to Avibactam 0.5gm	1 Vial	M/s Protech Telelinks / M/s Samarth Life Sciences Pvt. Ltd.	2074.74
2.	Vitamin D3 Oral Solution	Each 5ml contains: Cholecalciferol                                      IP 600000 IU (In Nano Droplet form)	1ml	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd.	11.63
3.	Telmisartan and Chlorthalidone Tablet	Each film coated tablet                        contains: Telmisartan IP 40mg Chlorthalidone                                      IP 12.50mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd.	7.39
4.	Telmisartan and Amlodipine Tablet	Each                        uncoated bilayered                           tablet contains: Telmisartan IP  80mg Amlodipine Besilate IP eq. Amlodipine 5mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd.	13.21

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos by The Health Master, click on the below YouTube icon:

• Fire explosion at Aurore Pharmaceuticals
  November 21, 2024
• Drug recall: Cipla recalls over 1.8k boxes of this drug
  November 21, 2024
• USFDA issued Form 483 with 7 observations to Dr Reddy’s
  November 20, 2024
• NPPA Revises Ceiling Prices of these Key Drugs
  November 20, 2024
• Approval of Anti Cancer drug Nivolumab for new Indication
  November 19, 2024
• Trump 2.0 Agenda: A Boon for Indian Pharma Industry?
  November 19, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: